Artificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Artificial Intelligence
• Biomarker Discovery

Background:

• Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) treatment, but patient response varies significantly.
• Current biomarkers for predicting ICI efficacy in NSCLC are limited, creating a need for improved predictive tools.
• Artificial intelligence (AI) is emerging as a powerful tool for analyzing complex biological data in cancer research.

Purpose of the Study:

• To review the application of AI in predicting immunotherapy efficacy for NSCLC patients.
• To explore how multi-omics data integration with AI can enhance biomarker discovery for immunotherapy response.
• To discuss the challenges and future directions of AI in precision medicine for NSCLC.

Main Methods:

• Integration of diverse multi-omics data, including radiomics, pathomics, genomics, transcriptomics, proteomics, and microbiomics.
• Application of AI algorithms for modeling clinical data and predicting patient prognosis and treatment response.
• Review of existing literature on AI-driven prediction of immunotherapy efficacy and toxicities in NSCLC.

Main Results:

• AI models integrating multi-omics data show promise in identifying NSCLC patients likely to respond to immunotherapy.
• AI facilitates comprehensive biomarker discovery, potentially improving the prediction of both efficacy and toxicities of ICIs.
• AI-driven approaches can contribute to personalized treatment strategies in NSCLC.

Conclusions:

• AI holds significant potential to improve the prediction of immunotherapy efficacy in NSCLC, addressing limitations of current biomarkers.
• Further research and development are needed to overcome challenges like data standardization and interpretability for widespread clinical adoption.
• AI-powered precision medicine approaches are crucial for optimizing NSCLC treatment outcomes.